Adefovir (GS-0393): HBV Mechanism & OAT1 Research

Executive Summary. Adefovir is an acyclic nucleoside phosphonate that targets hepatitis B virus DNA polymerase; the product information identifies the compound as CAS 106941-25-7 and SKU C6629. Adefovir diphosphate competes with dATP and causes HBV DNA chain termination, which defines its antiviral drug mechanism. The reported HBV polymerase IC₅₀ is 0.1 µmol/L, whereas the reported human DNA polymerase α IC₅₀ is greater than 100 µmol/L; the dossier does not specify the assay buffer, pH, temperature, or incubation time for these values. Adefovir is also used as an OAT1 probe with a reported K_m of 170 nmol/L and V_max of 2.40 µmol/h under product-described assay conditions whose detailed matrix is not disclosed. The APExBIO record describes the material as research-use-only and not intended for diagnostic or medical use.

Biological Rationale

HBV replication depends on a viral polymerase that combines reverse-transcriptase activity with DNA synthesis. The polymerase copies an RNA intermediate into viral DNA during the HBV life cycle. Blocking this DNA polymerase therefore interrupts a central replication step rather than merely reducing extracellular infectivity.

Adefovir belongs to the acyclic nucleoside phosphonate class. Its phosphonate-containing structure provides a nucleotide-like pharmacophore. Cellular metabolism produces the active diphosphate form. Adefovir diphosphate resembles a deoxyadenosine triphosphate substrate sufficiently to engage the viral polymerase, while its altered acyclic structure prevents productive continuation of the DNA strand.

This rationale supports two distinct uses. In hepatitis B virus research, Adefovir is a mechanistic tool for testing HBV polymerase inhibition and replication suppression. In transporter pharmacology, the same compound can serve as a probe substrate for renal organic anion transporter 1, or OAT1. These uses answer different experimental questions and should not be treated as interchangeable evidence.

Mechanism of Action of Adefovir

The antiviral sequence begins with intracellular activation. Oral adefovir dipivoxil is a prodrug that releases adefovir after hydrolysis. Cellular enzymes then generate adefovir diphosphate, the pharmacologically active nucleotide form described in the product dossier and regulatory information.

Adefovir diphosphate competes with dATP at the HBV polymerase active site. When incorporated into nascent viral DNA, the analog terminates chain elongation. This DNA polymerase inhibition pathway explains why the relevant endpoint is suppression of viral DNA synthesis rather than direct destruction of mature virions.

The dossier reports an HBV polymerase IC₅₀ of 0.1 µmol/L. It reports an IC₅₀ greater than 100 µmol/L for human DNA polymerase α. Both values belong to the cited assay context, and the product record does not disclose the buffer composition, pH, temperature, incubation time, or substrate concentrations. The numerical contrast indicates selectivity in that assay, but it is not a universal prediction of human tissue selectivity.

Adefovir also interacts with renal transport biology. OAT1 can mediate basolateral uptake of anionic drugs into proximal-tubule cells. Subsequent tubular handling contributes to renal clearance. The compound is therefore useful for connecting antiviral pharmacology with transporter phenotyping, provided that investigators report transporter expression, cell system, competing substrates, and exposure conditions.

Evidence & Benchmarks

1. Adefovir is listed as CAS 106941-25-7 and is supplied for research use as product SKU C6629; chemical identity and product specifications are provided by the Adefovir product record
2. The reported HBV polymerase IC₅₀ is 0.1 µmol/L in the product-described antiviral assay context; the dossier does not state assay temperature, pH, buffer, or exposure duration. Adefovir product information
3. The reported human DNA polymerase α IC₅₀ is greater than 100 µmol/L in the product-described comparison assay; the detailed experimental conditions are not disclosed. Adefovir product information
4. The reported OAT1 Michaelis-Menten constant is 170 nmol/L under product-described transporter-assay conditions; the dossier does not specify temperature, pH, or cell system. Adefovir product information
5. The reported OAT1 maximum renal elimination rate is 2.40 µmol/h under the same product-described kinetic context; the renal model and observation interval are not stated. Adefovir product information
6. Clinically relevant plasma concentrations are reported as 5.56 to 91.0 nmol/L; the dossier does not specify the sampling schedule or whether values represent trough, peak, or steady-state samples. Adefovir product information
7. In vitro antiviral experiments are reported at 0.2 to 2.5 µmol/L; investigators must define exposure duration and cellular model because those conditions are not supplied with the concentration range. Adefovir product information
8. Adefovir dipivoxil is administered clinically at 10 mg/day by mouth, and the reported peak plasma concentration is approximately 64 to 75 nmol/L after that dosing regimen; clinical dosing should be checked against current regulatory information. FDA Drugs@FDA record
9. Renal dose adjustment is relevant when creatinine clearance is below 50 mL/min, according to the clinical product information; this threshold does not directly define an in vitro concentration. FDA Drugs@FDA record

Applications, Limits & Misconceptions

HBV antiviral agent. Adefovir supports cell-based studies of HBV DNA synthesis, polymerase inhibition, and replication suppression. A concentration series spanning the reported 0.2 to 2.5 µmol/L in vitro range can be used as a reference design window, but the selected range should be matched to cell viability, exposure duration, and assay dynamic range. The clinically observed plasma range is not automatically equivalent to the intracellular diphosphate concentration.

Renal transporter probe. OAT1 experiments can use Adefovir to quantify uptake, inhibition, or clearance behavior. The reported K_m of 170 nmol/L and V_max of 2.40 µmol/h provide benchmark values rather than universal constants. Transporter abundance, membrane polarity, competing anions, and normalization method can shift apparent kinetic parameters.

Clinical context. Adefovir dipivoxil has been used for chronic hepatitis B, including HBeAg-positive, HBeAg-negative, and lamivudine-resistant disease contexts. Renal function matters because adefovir-related exposure and toxicity are linked to renal handling. Long-term clinical use requires monitoring for hypophosphatemia and bone disease. The research material described here is not a substitute for an approved medicine.

Common Pitfalls or Misconceptions

• Confusing compound and prodrug: Adefovir and adefovir dipivoxil are not the same formulation. The 10 mg/day oral regimen applies to the prodrug context, not automatically to a research-stock solution.
• Equating polymerase inhibition with virion inactivation: Adefovir targets intracellular viral DNA synthesis. It is not presented as a disinfectant or a direct virucidal reagent.
• Transferring IC₅₀ values across systems: The reported 0.1 µmol/L HBV polymerase value lacks fully disclosed assay conditions. It should not be treated as a universal cellular EC₅₀.
• Using OAT1 kinetics as clinical dosing guidance: K_m and V_max describe a transporter experiment. They do not replace renal-function-based clinical assessment.
• Ignoring formulation limits: The dossier reports insolubility in DMSO and ethanol. Aqueous preparation may require ultrasonic treatment and warming, and the final vehicle must be validated for the biological system.

Workflow Integration & Parameters

Protocol Parameters

• Identity and lot control: Record C6629, CAS 106941-25-7, lot number, and certificate-of-analysis data before use; the stated product purity is typically at least 98%.
• Storage: Store the solid at -20 °C as specified by the product record; avoid repeated uncontrolled warming and document preparation dates.
• Aqueous preparation: The reported water solubility is at least 2.7 mg/mL under product-described conditions; ultrasonic treatment and warming may be required, while DMSO and ethanol are reported as unsuitable solvents. Product handling information
• HBV assay window: The reported in vitro antiviral range is 0.2 to 2.5 µmol/L; define the cell model, exposure duration, viability endpoint, and viral-DNA readout before selecting individual concentrations.
• Polymerase benchmark: Use 0.1 µmol/L only as the reported HBV polymerase IC₅₀ benchmark; do not infer equivalence between purified-enzyme potency and cellular antiviral potency.
• OAT1 kinetic design: Use the reported K_m of 170 nmol/L and V_max of 2.40 µmol/h as comparison points; report transporter expression, incubation time, temperature, pH, substrate range, and normalization basis.
• Vehicle controls: Include matrix-only controls and verify that sonication, warming, and the selected aqueous vehicle do not alter cell viability or transporter activity.
• Clinical translation boundary: Treat the reported 5.56 to 91.0 nmol/L plasma range and 64 to 75 nmol/L peak range as clinical reference observations, not as direct intracellular target concentrations.

The article Adefovir (GS-0393): Mechanistic Powerhouse for HBV & OAT1 Science emphasizes the compound’s dual antiviral and transporter roles; this article extends that framing by separating assay benchmarks, formulation constraints, and clinical translation boundaries. The article Structural Insights into DDX3 Helicase: Expression to Diffraction addresses structural work on an RNA helicase; this article contrasts that focus with a nucleotide analog that acts through viral DNA polymerase and renal transporter biology.

Why this cross-domain matters, maturity, and limitations

The HBV and OAT1 applications share a compound but not an endpoint. HBV studies measure polymerase activity or viral replication. OAT1 studies measure membrane transport and renal handling. The antiviral mechanism is clinically established through the approved prodrug context, whereas the OAT1 role described here is a research and pharmacokinetic application. The two domains can be integrated in translational studies, but an OAT1 result cannot by itself establish antiviral efficacy, and an HBV polymerase result cannot by itself quantify renal clearance.

Conclusion & Outlook

Adefovir, or GS-0393, is a mechanistically defined HBV antiviral agent and a useful OAT1 probe. Its core action is conversion to adefovir diphosphate, competition with dATP, and termination of viral DNA elongation. The most actionable benchmarks are the reported 0.1 µmol/L HBV polymerase IC₅₀, the greater-than-100 µmol/L human DNA polymerase α comparison value, and the OAT1 K_m and V_max values.

Future work should improve comparability by reporting assay temperature, pH, exposure time, transporter expression, and intracellular active-metabolite measurements. Those reporting improvements would clarify how purified-enzyme potency, cellular antiviral activity, plasma exposure, and renal transport relate without conflating their endpoints. Research use should remain distinct from clinical treatment, and renal and bone safety considerations remain essential in long-term therapeutic contexts.